Endocrine-disrupting chemicals (EDCs) are compounds that interfere with the body's hormonal signalling systems. The term covers a wide range of mechanisms and a wide range of chemicals. What they share is the ability to alter the synthesis, secretion, transport, metabolism, binding, or elimination of natural hormones. Because hormones regulate virtually every physiological process, from metabolism and reproduction to immune function and brain development, disrupting them at critical points can have wide-ranging consequences.
How hormones work
The endocrine system uses chemical messengers (hormones) to coordinate physiological functions across the entire body. Hormones are produced in glands (thyroid, adrenals, ovaries, testes, pituitary, pancreas) and travel through the bloodstream to target cells bearing matching receptors. The lock-and-key metaphor is useful but incomplete: receptor binding triggers a cascade of cellular responses that can amplify or suppress gene expression, enzyme activity, and cellular behaviour. The system is highly sensitive to concentration: hormones operate in the picomolar to nanomolar range, meaning effects can occur at extraordinarily low doses.
How EDCs interfere
Endocrine disruptors interfere through several mechanisms. Agonists (like BPA and parabens) bind to receptors and mimic the effect of natural hormones, producing hormonal responses when no hormone is present. Antagonists (like some pesticides) block receptors, preventing natural hormones from binding. Others alter hormone synthesis, increasing or decreasing how much of a given hormone is produced. Still others interfere with transport proteins that carry hormones through the bloodstream, or with the enzymes that metabolise hormones. PFAS, for example, interfere with thyroid hormone transport proteins, reducing the availability of thyroid hormone to target tissues. Organophosphates inhibit cholinesterase, an enzyme involved in nerve signal termination.
The dose paradox
Classical toxicology assumes a linear dose-response relationship: higher dose produces greater effect. Endocrine disruptors frequently violate this assumption. Because hormone systems evolved to respond to very low concentrations with high sensitivity, EDCs can produce non-monotonic (non-linear) dose-response curves. In multiple studies, low doses of BPA produced stronger effects on receptor signalling than high doses. This matters for regulation: studies designed around high-dose toxicology testing can miss effects that occur specifically at low, environmentally relevant concentrations. The US National Toxicology Program and the European Food Safety Authority have both acknowledged this challenge in their risk assessments of BPA.
Key EDCs to know
The highest-evidence EDCs are BPA and its analogues (food packaging, receipts), phthalates (fragrance, PVC plastics, personal care), PFAS (non-stick cookware, water, food packaging), parabens (cosmetics and personal care), organophosphate pesticides (food and domestic use), polybrominated diphenyl ethers and their replacements (furniture foam, electronics), and synthetic oestrogens in the water supply from pharmaceutical hormones. These are the compounds with the strongest evidence base linking consumer exposure concentrations to biological effects in population studies.
Why regulation is slow
Chemical regulation in most jurisdictions operates under a presumption of safety: a chemical is permitted until proven harmful. The burden of proof lies with regulators, not with manufacturers. Demonstrating harm requires extensive data collection, expert review, and regulatory process that can take 10 to 20 years from identification of concern to regulatory action. During this period, the chemical remains in use. PFAS were identified as a potential health concern in the 1990s; enforceable limits in US drinking water arrived in 2024. EDC research also suffers from the non-monotonic dose problem described above, which makes standard regulatory toxicology frameworks poorly suited to characterising risk.